Regulated Cell Death Pathways in Doxorubicin-induced Cardiotoxicity

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2021 Apr 2

PMID 33795647

Citations 191

Authors

Effimia Christidi

Liam R Brunham

Affiliations

Soon will be listed here.

Abstract

Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug. The mechanisms by which doxorubicin kills cardiomyocytes has been elusive and despite extensive research the exact mechanisms remain unknown. This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis. Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.

Citing Articles

Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies.

Sun Y, Xiao L, Chen L, Wang X Cardiovasc Drugs Ther. 2025; .

PMID: 40009315 DOI: 10.1007/s10557-025-07673-6.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects.

Ru Q, Li Y, Zhang X, Chen L, Wu Y, Min J Bone Res. 2025; 13(1):27.

PMID: 40000618 PMC: 11861620. DOI: 10.1038/s41413-024-00398-6.

Irisin Mitigates Doxorubicin-Induced Cardiotoxicity by Reducing Oxidative Stress and Inflammation via Modulation of the PERK-eIF2α-ATF4 Pathway.

Zhang Z, Yu X, Li J, Shen X, Fu W, Liu Y Drug Des Devel Ther. 2025; 19:1067-1081.

PMID: 39974610 PMC: 11837746. DOI: 10.2147/DDDT.S492691.

Nanoscale strategies: doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approaches.

Lim J, Yong Y, Dewi F, Chan S, Lim V Drug Deliv Transl Res. 2025; .

PMID: 39955406 DOI: 10.1007/s13346-025-01790-3.

Downregulated TRIM35 Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress and Inflammation via Inhibiting TLR4/NF-κB Pathway.

Hu Y, Wang S, Zhang C, He F, Jiang Y, Chen R Cardiovasc Drugs Ther. 2025; .

PMID: 39954170 DOI: 10.1007/s10557-025-07672-7.

References

Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

Swain S, Whaley F, Ewer M . Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97(11):2869-79. DOI: 10.1002/cncr.11407. View

Lefrak E, Pitha J, ROSENHEIM S, Gottlieb J . A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2):302-14. DOI: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. View

Shi Y, Moon M, Dawood S, McManus B, Liu P . Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011; 36(4):296-305. DOI: 10.1007/s00059-011-3470-3. View

Zhang S, Liu X, Bawa-Khalfe T, Lu L, Lyu Y, Liu L . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012; 18(11):1639-42. DOI: 10.1038/nm.2919. View

Henriksen P . Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2017; 104(12):971-977. DOI: 10.1136/heartjnl-2017-312103. View

Tang D, Kang R, Vanden Berghe T, Vandenabeele P, Kroemer G . The molecular machinery of regulated cell death. Cell Res. 2019; 29(5):347-364. PMC: 6796845. DOI: 10.1038/s41422-019-0164-5. View

Galluzzi L, Vitale I, Aaronson S, Abrams J, Adam D, Agostinis P . Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018; 25(3):486-541. PMC: 5864239. DOI: 10.1038/s41418-017-0012-4. View

Elmore S . Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4):495-516. PMC: 2117903. DOI: 10.1080/01926230701320337. View

10.

Hansen M, Rubinsztein D, Walker D . Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol. 2018; 19(9):579-593. PMC: 6424591. DOI: 10.1038/s41580-018-0033-y. View

11.

Dikic I, Elazar Z . Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018; 19(6):349-364. DOI: 10.1038/s41580-018-0003-4. View

12.

Feng Y, He D, Yao Z, Klionsky D . The machinery of macroautophagy. Cell Res. 2013; 24(1):24-41. PMC: 3879710. DOI: 10.1038/cr.2013.168. View

13.

Wu R, Wang H, Yu H, Cui X, Xu M, Xu X . Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016; 244:149-58. DOI: 10.1016/j.cbi.2015.12.010. View

14.

Wang X, Wang X, Chen H, Wu D, Chen J, Wang X . Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol. 2014; 88(3):334-50. DOI: 10.1016/j.bcp.2014.01.040. View

15.

Pointon A, Walker T, Phillips K, Luo J, Riley J, Zhang S . Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One. 2010; 5(9):e12733. PMC: 2939875. DOI: 10.1371/journal.pone.0012733. View

16.

Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y . Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS One. 2012; 7(10):e47351. PMC: 3471849. DOI: 10.1371/journal.pone.0047351. View

17.

Sun A, Cheng Y, Zhang Y, Zhang Q, Wang S, Tian S . Aldehyde dehydrogenase 2 ameliorates doxorubicin-induced myocardial dysfunction through detoxification of 4-HNE and suppression of autophagy. J Mol Cell Cardiol. 2014; 71:92-104. DOI: 10.1016/j.yjmcc.2014.01.002. View

18.

Andreadou I, Mikros E, Ioannidis K, Sigala F, Naka K, Kostidis S . Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol. 2014; 69:4-16. DOI: 10.1016/j.yjmcc.2014.01.007. View

19.

Wang S, Song P, Zou M . Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem. 2012; 287(11):8001-12. PMC: 3318690. DOI: 10.1074/jbc.M111.315812. View

20.

Yu S, Liu L, Li P, Li J . Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg. 2012; 61(3):223-8. DOI: 10.1055/s-0032-1311548. View